keyword
MENU ▼
Read by QxMD icon Read
search

EGFR inhibitor skin effect

keyword
https://www.readbyqxmd.com/read/29590083/efficacy-of-gefitinib-and-radiotherapy-combination-in-indonesian-patients-with-lung-adenocarcinoma
#1
Elisna Syahruddin, Aida Lufti Huswatun, Ari Prabowo, Jamal Zaini, Fariz Nurwidya, Achmad Hudoyo, Anwar Jusuf
INTRODUCTION: Combinations of gefitinib and radiotherapy have been observed to have synergistic and anti-proliferative effects on lung cancer in vitro. In the clinical setting, patients who presented with respiratory difficulties such as superior vena cava syndrome (SVCS), radiotherapy should be given immediately to address the emergency while waiting for the results of epidermal growth factor receptor (EGFR) mutation test. However, there has been no study that described the role of radiotherapy in Indonesian patients with EGFR-mutant lung adenocarcinoma...
March 1, 2018: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
https://www.readbyqxmd.com/read/29576427/dermatologic-toxicity-occurring-during-anti-egfr-monoclonal-inhibitor-therapy-in-patients-with-metastatic-colorectal-cancer-a-systematic-review
#2
REVIEW
Mario E Lacouture, Milan Anadkat, Aminah Jatoi, Tamer Garawin, Chet Bohac, Edith Mitchell
Monoclonal antibody inhibitors of the epidermal growth factor receptor (EGFR) have been shown to improve outcomes for patients with metastatic colorectal cancer (mCRC) without RAS gene mutations. However, treatment with anti-EGFR agents can be associated with toxicities of the skin, nails, hair, and eyes. Because these dermatologic toxicities can result in treatment discontinuation and affect patient quality of life, their management is an important focus when administering anti-EGFR monoclonal antibodies. The present systematic review describes the current data reporting the nature and incidence of, and management and treatment options for, dermatologic toxicities occurring during anti-EGFR treatment of mCRC...
December 13, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29549700/cutaneous-toxicities-of-epidermal-growth-factor-receptor-inhibitors-a-prospective-study-in-60-asian-patients
#3
Leena Chularojanamontri, Papapit Tuchinda, Chayanee Likitwattananurak, Kamolwan Pongparit, Chuda Rujitharanawong, Suthinee Ithimakin, Kanokvalai Kulthanan
BACKGROUND: Several prospective studies have been conducted in epidermal growth factor receptor (EGFR) inhibitor-related cutaneous reactions in Caucasian patients, but prospective studies in Asian populations are scarce. OBJECTIVE: To investigate the cutaneous side effects of EGFR inhibitors in Asian cancer patients and to assess tumor response to dermatologic manifestations. METHODS: Sixty patients with lung or colorectal cancer who were receiving EGFR inhibitors were prospectively followed for at least one year by oncologists and dermatologists...
March 12, 2018: Asian Pacific Journal of Allergy and Immunology
https://www.readbyqxmd.com/read/29526950/pulmonary-adenocarcinoma-harboring-both-an-egfr-mutation-and-alk-rearrangement-presenting-a-stable-disease-to-erlotinib-and-a-partial-response-to-alectinib-a-case-report
#4
Akira Yokoyama, Atsuhisa Tamura, Kazuko Miyakawa, Kei Kusaka, Masahiro Shimada, Takashi Hirose, Hirotoshi Matsui, Masashi Kitani, Akira Hebisawa, Ken Ohta
A 63-year-old woman with pulmonary adenocarcinoma (stage IIIB) that was positive for an epidermal growth factor receptor (EGFR) mutation and an anaplastic lymphoma kinase (ALK) rearrangement was treated with erlotinib as the first-line treatment, resulting in a stable disease. Due to skin rashes, fatigue and anorexia, erlotinib was suspended on erlotinib day 44. Alectinib was administered as the second-line treatment, exhibiting a partial response. On alectinib day 56, drug-induced lung injury forced suspension of alectinib, which was cured with corticosteroid therapy...
March 9, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29507555/the-incidence-and-management-of-cutaneous-adverse-events-of-the-epidermal-growth-factor-receptor-inhibitors
#5
REVIEW
Witold Owczarek, Monika Słowińska, Aleksandra Lesiak, Magdalena Ciążyńska, Aldona Maciąg, Elwira Paluchowska, Luiza Marek-Józefowicz, Rafał Czajkowski
Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including those of the head and neck area, non-small-cell lung cancer, and colorectal, cervical, prostate, breast, ovary, stomach, and pancreatic cancer. The EGFR inhibitors are used at present in the treatment of such cancers. Skin lesions that develop during and after cancer treatment may be due to specific cytostatics, molecular-targeted drugs, radiation therapy, complementary therapy, or the cancer itself, and hence knowledge is essential to distinguish between them...
October 2017: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/29491117/skin-rash-can-be-a-useful-marker-for-afatinib-efficacy
#6
Shingo Nasu, Hidekazu Suzuki, Takayuki Shiroyama, Ayako Tanaka, Kaori Iwata, Noriko Ryota, Yuki Ueda, S O Takata, Kentaro Masuhiro, Satomu Morita, Naoko Morishita, Norio Okamoto, Tomonori Hirashima
BACKGROUND/AIM: Although afatinib has a strong efficacy, it can be toxic; hence, we aimed to determine markers of response to afatinib in order to assess prognosis. PATIENTS AND METHODS: Information on clinical background, therapeutic effects, and adverse events was collected retrospectively at one Institution from patients treated with afatinib as initial epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). We examined the relationship between different adverse events and their effects on prognosis...
March 2018: Anticancer Research
https://www.readbyqxmd.com/read/29485795/drug-induced-photosensitivity-a-continuing-diagnostic-challenge
#7
REVIEW
Liborija Lugović-Mihić, Tomislav Duvančić, Iva Ferček, Petra Vuković, Iva Japundžić, Diana Ćesić
When taking different drugs, their possible side effects on the skin should be considered, including skin reactions connected to photosensitivity. This photosensitivity caused by drugs can appear as phototoxic reactions (which occur more often) or photoallergic reactions (which occur less often and include allergic mechanisms). The following drugs stand out as medications with a high photosensitivity potential: nonsteroidal anti-inflammatory drugs (NSAIDs), cardiovascular drugs (such as amiodarone), phenothiazines (especially chlorpromazine), retinoids, antibiotics (sulfonamides, tetracyclines, especially demeclocycline and quinolones), etc...
June 2017: Acta Clinica Croatica
https://www.readbyqxmd.com/read/29462253/overview-of-current-systemic-management-of-egfr-mutant-nsclc
#8
W-H Hsu, J C-H Yang, T S Mok, H H Loong
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). Several phase III studies have demonstrated the superiority of gefitinib, erlotinib (first generation of TKIs) or afatinib (second generation) to chemotherapy in progression-free survival and response rates. Drug-related toxicities, such as diarrhoea, acneiform skin rash, mucositis, and paronychia, are frequently encountered in patients who receive EGFR TKIs...
January 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29450147/lemongrass-cymbopogon-flexuosus-essential-oil-demonstrated-anti-inflammatory-effect-in-pre-inflamed-human-dermal-fibroblasts
#9
Xuesheng Han, Tory L Parker
Lemongrass ( Cymbopogon flexuosus ) essential oil (LEO), which has citral as its main component, has exhibited anti-inflammatory effect in both animal and human cells. In this study, we evaluated the anti-inflammatory activity of a commercially available LEO in pre-inflamed human dermal fibroblasts. We first studied the impact of LEO on 17 protein biomarkers that are critically associated with inflammation and tissue remodeling. LEO significantly inhibited production of the inflammatory biomarkers vascular cell adhesion molecule 1 (VCAM-1), interferon gamma-induced protein 10 (IP-10), interferon-inducible T-cell alpha chemoattractant (I-TAC), and monokine induced by gamma interferon (MIG); decreased levels of the tissue remodeling biomarkers collagen-I and III, epidermal growth factor receptor (EGFR), and plasminogen activator inhibitor (PAI-1); and inhibited the immunomodulatory biomarker macrophage colony-stimulating factor (M-CSF)...
June 2017: Biochimie Open
https://www.readbyqxmd.com/read/29450144/anti-inflammatory-tissue-remodeling-immunomodulatory-and-anticancer-activities-of-oregano-origanum-vulgare-essential-oil-in-a-human-skin-disease-model
#10
Xuesheng Han, Tory L Parker
The use of oregano ( Origanum vulgare ) essential oil (OEO) has become popular in skin care products. However, scientific research regarding its effects on human skin cells is scarce. In this study, we investigated the biological activity of a commercially available OEO, which is high in carvacrol content, in a human skin cell disease model. OEO induced marked antiproliferative effects and significantly inhibited several inflammatory biomarkers, including monocyte chemoattractant protein 1 (MCP-1), vascular cell adhesion molecule 1 (VCAM-1), intracellular cell adhesion molecule 1 (ICAM-1), interferon gamma-induced protein 10 (IP-10), interferon-inducible T-cell alpha chemoattractant (I-TAC), and monokine induced by gamma interferon (MIG)...
June 2017: Biochimie Open
https://www.readbyqxmd.com/read/29387237/bioinformatics-analysis-of-gene-expression-alterations-conferring-drug-resistance-in-tumor-samples-from-melanoma-patients-with-egfr-activating-braf-mutations
#11
Yang Yu, Xueer Wang, Qinglin Li, Min Zhang, Pengcheng Xu, Yinghua Chen, Yuan Yan, Lin Zhang
Melanoma is a highly malignant tumor of the skin melanocytes. Patients with this cancer have a high frequency (~50%) of oncogenic BRAF mutations, particularly BRAF V600E. Treatments for melanoma often target BRAF mutations or involve mitogen-activated protein kinase kinase/extracellular signal-regulated kinase inhibitors. A major challenge in melanoma treatment is resistance to BRAF inhibitor treatment, which may be enhanced by the BRAF mutation itself and/or epidermal growth factor receptor (EGFR) activation, leading to poor prognosis...
January 2018: Oncology Letters
https://www.readbyqxmd.com/read/29377278/hypertrichosis-of-the-pinnae-in-a-patient-using-panitumumab
#12
C Baykal, G Babuna Kobaner
Various subgroups of epidermal growth factor receptor inhibitors (EGFRIs) are increasingly being used in the treatment of several cancers. However, as a generalized class effect, they are frequently associated with a wide spectrum of dermatological adverse reactions affecting skin, hair and nail of varying severity.A 53-year-old male with metastatic rectal cancer receiving every two weeks infusions of panitumumab, a human monoclonal antibody targeting EGFR, presented with a generalized acneiform papulopustular eruption (Grade 3 according to the Common Terminology Criteria for Adverse Events version 4...
January 29, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29191595/phase-2-study-of-intermittent-pulse-dacomitinib-in-patients-with-advanced-non-small-cell-lung-cancers
#13
Helena A Yu, Myung-Ju Ahn, Byoung Chul Cho, David E Gerber, Ronald B Natale, Mark A Socinski, Nagdeep Giri, Susan Quinn, Eric Sbar, Hui Zhang, Giuseppe Giaccone
BACKGROUND: Dacomitinib is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Pre-clinical data suggest that intermittent pulsatile dosing of dacomitinib may result in inhibition of EGFR T790M. METHODS: We evaluated safety, pharmacokinetics and efficacy of intermittent pulsatile dacomitinib in both molecularly unselected patients and patients with lung cancers harboring EGFR T790M (Clinical Trial Registration Number NCT01858389)...
October 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29135755/management-of-skin-toxicity-caused-by-epidermal-growth-factor-receptor-inhibitors-an-evidence-based-implementation-project
#14
Xiaolu Guo, Micah D J Peters, Zhenqi Lu
BACKGROUND: Epidermal growth factor receptor inhibitors (EGFRIs) bind to and inhibit epidermal growth factor receptors (EGFRs) in cancer cells, slowing/preventing tumor growth. As a type of "targeted therapy", they have demonstrated therapeutic effects on solid tumors including colorectal, lung, and head and neck cancers. While effective, various skin reactions are associated with EGFRI therapy which can lead to dose modification or discontinuation as well as discomfort, pain and reduced quality of life...
November 2017: JBI Database of Systematic Reviews and Implementation Reports
https://www.readbyqxmd.com/read/29123409/preventive-effect-of-kampo-medicine-hangeshashin-to-tj-14-plus-minocycline-against-afatinib-induced-diarrhea-and-skin-rash-in-patients-with-non-small-cell-lung-cancer
#15
Masao Ichiki, Hiroshi Wataya, Kazuhiko Yamada, Nobuko Tsuruta, Hiroaki Takeoka, Yusuke Okayama, Jun Sasaki, Tomoaki Hoshino
Purpose: Diarrhea and oral mucositis induced by afatinib can cause devastating quality of life issues for patients undergoing afatinib treatment. Several studies have shown that hangeshashin-to (TJ-14) might be useful for chemotherapy-induced diarrhea and oral mucositis. In this study, we investigated the prophylactic effects of TJ-14 for afatinib-induced diarrhea and oral mucositis and minocycline for afatinib-induced skin rash. Patients and methods: First- and second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have become the standard first-line treatment in patients with EGFR-mutated non-small cell lung cancer...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29116406/a-survey-of-patient-and-physician-acceptance-of-skin-toxicities-from-anti-epidermal-growth-factor-receptor-therapies
#16
Bernd Tischer, Martina Bilang, Matthias Kraemer, Philippe Ronga, Mario E Lacouture
BACKGROUND: Inhibition of the epidermal growth factor receptor (EGFR) extends patient survival in multiple tumor types. Skin toxicities are the most common adverse event (AE) elicited by EGFR inhibitors. Here, we provide deeper insights into patients' and physicians' acceptance of the risk/benefit trade-offs of skin toxicities during cancer therapy, including comparison of their perceptions and experiences with dermatologic AEs. METHODS: A multinational survey of 195 patients and 120 physicians was conducted to gauge attitudes regarding skin toxicities as an AE during cancer therapy...
November 7, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29064427/the-mek-inhibitors-trametinib-and-cobimetinib-induce-a-type-i-interferon-response-in-human-keratinocytes
#17
Daniela Lulli, Maria Luigia Carbone, Saveria Pastore
Mitogen-activated protein kinase kinases (MEK) 1 and 2 have crucial roles in tumorigenesis, cell proliferation, and protection from apoptosis, and their inhibition is therefore an attractive therapeutic strategy in cancer. Orally available and highly selective MEK inhibitors have been developed and assessed in numerous clinical trials, either alone or in combination with cytotoxic chemotherapy and/or other targeted agents. Of note, a complex picture of class-specific adverse effects associates with these drugs, frequently including inflammatory skin rash...
October 24, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29056570/activity-and-safety-of-azd3759-in-egfr-mutant-non-small-cell-lung-cancer-with-cns-metastases-bloom-a-phase-1-open-label-dose-escalation-and-dose-expansion-study
#18
Myung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, Sang-We Kim, Jong Seok Lee, Jin-Seok Ahn, Tae Min Kim, Chia-Chi Lin, Hye Ryun Kim, Thomas John, Steven Kao, Jonathan W Goldman, Wu-Chou Su, Ronald Natale, Sarit Rabbie, Bryony Harrop, Philip Overend, Zhenfan Yang, James Chih-Hsin Yang
BACKGROUND: CNS metastases-including brain and leptomeningeal metastases-from epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) are associated with poor prognosis. AZD3759 is a novel EGFR tyrosine kinase inhibitor with high capability to penetrate the blood-brain barrier. We aimed to assess the safety, tolerability, pharmacokinetics, and efficacy of AZD3759 in patients with EGFR-mutant NSCLC with brain and leptomeningeal metastases. METHODS: This open-label, multicentre, phase 1 study was undertaken at 11 centres and hospitals in Australia, South Korea, Taiwan, and the USA...
November 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28966961/role-of-systemic-antibiotics-in-preventing-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-induced-skin-toxicities
#19
REVIEW
Philomena Charlotte Dsouza, Shiyam Kumar
The epidermal growth factor receptor (EGFR) is actively involved in the growth of multiple tumor types and has been found as an effective treatment target in various solid cancers, for example, lung cancer and head and neck cancer. Of effective drugs which target and inhibit EGFR functions, tyrosine kinase inhibitors have shown promising results, albeit at a cost of side effects, skin toxicity being the most common. This article provides an evidence-based strategy to oncology nurse practitioners in dealing with such toxicity...
October 2017: Asia-Pacific Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28932126/dermopathy-associated-with-cetuximab-and-panitumumab-investigation-of-the-usefulness-of-moisturizers-in-its-management
#20
Shoichi Watanabe, Motoki Nakamura, Hiroki Takahashi, Masayasu Hara, Kei Ijichi, Daisuke Kawakita, Akimichi Morita
AIMS: Limited data regarding the objective evaluation of skin exsiccation caused by epidermal growth factor receptor (EGFR) inhibitors exist. Objective indices were applied to evaluate the usefulness of a moisturizer against skin exsiccation associated with the use of EGFR inhibitors in cancer patients. PATIENTS AND METHODS: Patients with either colorectal or head and neck cancer treated with either cetuximab or panitumumab were randomly assigned 1:2 to the prophylactic-treatment arm, where participants received prophylactical moisturizer treatment (heparinoid preparation, Hirudoid(®)), or to the symptomatic-treatment arm, where moisturizer was applied after the onset of cutaneous symptoms...
2017: Clinical, Cosmetic and Investigational Dermatology
keyword
keyword
47998
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"